Xurodopa 125 Tablet combines Levodopa 100mg with Carbidopa 25mg, a potent therapy for Parkinson’s disease. Levodopa increases dopamine levels in the brain to improve motor function, while Carbidopa enhances its effectiveness and minimizes side effects such as nausea and vomiting.
This combination belongs to the neurology and CNS segment and is prescribed for managing tremors, rigidity, bradykinesia, and other Parkinsonian symptoms. The higher Carbidopa dose in this formulation ensures better Levodopa availability and improved patient outcomes.
Xurodopa 125 is widely used in long-term Parkinson’s management, offering flexibility for dose adjustments according to patient response. Its consistent efficacy makes it a high-demand product across hospitals, neurology clinics, and specialty pharmacies.
For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Xurodopa 125 Tablet provides a profitable B2B opportunity in the anti-Parkinson segment with steady demand and significant growth potential across India.